Skip to main content
. Author manuscript; available in PMC: 2009 Oct 3.
Published in final edited form as: Clin Infect Dis. 2009 Mar 1;48(5):642–649. doi: 10.1086/597007

Figure 1.

Figure 1

Serial plasma viral loads, CD4 cell counts, and viral coreceptor use in 4 patients who developed lymphoma while receiving vicriviroc (VCV) during AIDS Clinical Trials Group A5211. A, Case 1 (Hodgkin lymphoma [HL]). B, Case 2 (non-Hodgkin lymphoma [NHL]). C, Case 3 (HL). D, Case 4 (NHL). HIV RNA levels are represented by closed circles, and CD4 cell counts are represented by open squares. Vertical arrows denote the time of lymphoma diagnosis. For patients 1 and 3, the lymphoma diagnosis occurred after the last available CD4 T cell count and plasma HIV-1 RNA load. Patient 1 had a screening coreceptor use assay (Trofile) performed 2 weeks prior to study entry that demonstrated CCR5-using virus only. At study entry and at all subsequent time points analyzed, however, dual-mixed virus was detected. Protocol-defined virologic failure was met when patients did not achieve a confirmed reduction in HIV-1 RNA load of ≥1 log10 copies/mL by week 16. DM, both CCR5- and CXCR4-using viruses detected; R5, CCR5-using virus only detected; rHL, recurrent HL.